NasdaqGS:TSHABiotechs
Why Taysha Gene Therapies (TSHA) Is Down 6.3% After Rett Trial Progress And Insider Stock Sales - And What's Next
Taysha Gene Therapies recently reported progress in its TSHA-102 gene therapy program for Rett syndrome, including dosing the first patient in the pivotal REVEAL trial and securing FDA alignment on the study design, while senior executives disclosed significant insider stock sales.
This combination of clinical and regulatory milestones with insider activity offers a rare window into both the program’s momentum and leadership’s capital decisions.
We’ll now examine how the FDA’s alignment on...